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one year post-discharge and compared between cohorts who receive and did not 
receive guideline recommended care using a probit regression model with instru-
mental variables. Results: One-fourth (29%) of the patients with COPD-related hos-
pitalizations/ED visits were identified as recipients of the guideline recommended 
care. Receiving guideline recommended care was associated with a reduction of 
4.4 percentage points in the probability of having subsequent COPD exacerbation 
requiring hospital admission/ED visits (p-value = 0.837). Analysis focusing on the 
follow up visit alone shows that having follow up visits were significantly associ-
ated (p-value = 0.018) with a reduction in the probability (32.8 percentage points) of 
having subsequent COPD exacerbation requiring hospital admission/ED visits, while 
the use of maintenance medication was associated with an increase in the prob-
ability (19.5 percentage points) of having subsequent COPD exacerbation requiring 
hospital admission/ED visits (p-value = 0.337). ConClusions: The use of guideline 
recommended care, especially in the use of follow up care, was significantly associ-
ated with the reduction in the probability of having subsequent COPD exacerbation 
requiring hospital admission/ED.
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objeCtives: Poor or non-adherence causes medical and psychosocial complica-
tions for patients and represents a considerable financial burden for health care 
systems worldwide. Medication adherence problems have not been routinely 
highly valued by health technology assessment (HTA) bodies in their evaluation 
assessments. In this study we assess the extent to which leading HTA bodies con-
sider the value of medication adherence in their reimbursement decision mak-
ing. Methods: Evaluation of published assessments made from 2010 to 2013 in 
five leading HTA bodies (Canadian Agency for Drugs and Technologies in Health 
(CADTH), the French National Authority for Health (HAS), England’s National 
Institute of Health and Care Excellence (NICE), the Australian Pharmaceutical 
Benefits Advisory Committee (PBAC) and the Scottish Medicines Consortium (SMC)) 
were reviewed for asthma, hypertension, diabetes, multiple sclerosis, psychological 
disorders and alcohol dependence. The primary outcome measure was to identify 
the number of assessments in which HTA bodies have considered adherence as 
a value message. Results: A total of 405 evaluation assessments were submit-
ted to HTA bodies for the above stated indications and timeframe. Out of these 
assessments, adherence was discussed in 65 (16.1%) of the assessments. However, 
adherence was not considered valuable for reimbursement decision making by HTA 
bodies in 19 of these 65 assessments. In the remaining 46 assessments, adherence 
was considered as a value message while making reimbursement decisions by the 
HTA bodies but it did not impact the final reimbursement decision in 79% of the 
instances. ConClusions: Leading HTA bodies have not considered medication 
adherence as a key metric in their reimbursement decision making.
HS3
Had tHe indiVidual Medical burden of baSic HealtH inSurance 
ParticiPantS really been alleViated in 2009-2012?
Cui B1, Wang L2, Xiong X2, Li J2
1Peking University, Beijing, China, 2China Health Insurance Research Association, Beijing, China
objeCtives: To analyze the out-of-pocket medical expenses of Basic Health 
Insurance participants between 2009 and 2012, and determine whether the indi-
vidual medical burden has been alleviated really in the health care reform from 
2009. Methods: This study used the data from the National Sample Survey on 
Medical Service Utilization of Basic Medical Insurance participants in 2009-2012.
This survey involved about 375 thousands in-patients with BMI from about 70 cit-
ies all over the country. All the actual claim data of medical expenses and medical 
care utilization from 2009 to 2012 were collected. Descriptive analysis was applied 
to the data and the related payment policies of BMI were reviewed. Results: 1) 
The total medical expenses burden of the BMI in-patients is keeping a high speed 
growth between 2009 and 2012, increased from about US$33 billion to about US$64.5 
billion (increased 25% per year). 2) The inpatient expenses presented a left skewed 
distribution. Over 55% of the expense burden came from 20% cases spending above 
US$3200. 3) The out-of-pocket rates of urban employee and residents were about 
29% and 49% respectively, and both of them presented a U-type pattern. The inpa-
tients spending below US$800 or above US$3200 had a higher burden. 4) The indi-
vidual medical burden presented an increase tendency with the increase of the 
hospital level. ConClusions: Generally, health insurance eased the economic bur-
den of inpatients and made out-of-pocket expense acceptable. But the individual 
burden for those inpatients with expenses above US$3200 had not been alleviated 
enough. New measures should be pursued to make further reduce, such as raising 
the reimbursement ceiling and providing new supplementary health insurance for 
severe illness. The increase speed of total medical burden should be controlled by 
lean formula management. The patients with commonly encountered illness should 
be guided to basic-level hospitals and supervision on medical service utilization 
should also be strengthened to control the irrational medical cost.
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objeCtives: To evaluate the perception of hospital pharmacists regarding quality of 
pharmaceutical care services in Khyber Pakhtunkhwa, Pakistan. Methods: Qualitative 
assessment was implemented. A semi-structured interview guide was developed 
and face to face interviews were conducted. Hospital pharmacists was interviewed 
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objeCtives: Although the evidence showed the risks of using sedative benzo-
diazepine (BZD) and long-terms use of non-BZD hypnotics (i.e., Z-drugs) among 
the elderly, it is still unavoidable to use these medications for the elderly to solve 
their insomnia problems. This study aimed to describe the utilization of hypnotic 
medications for outpatients in a 2000-bed medication center in Taiwan. Methods: 
We conducted a secondary data analysis using China Medical University Hospital 
(CMUH) in-house databases. From 2007 to 2013, those outpatients ever prescribed 
with, estazolam, lorazepam, diazepam, alprazolam, zolpidem and zopiclone were 
of interest. The prescription prevalence rates of these drugs, its average number of 
defined daily dose (DDD), prescriber specialties and demographic characteristics of 
patients were examined using descriptive analyses. Results: Those elder patients 
were prescribed with 133 ±158 DDD of Z-drugs in CMUH in 2007. 7.6% of them used 
Z-drugs exceed 365DDD within one year. In 2009, more than 40% of all 15,815 pre-
scriptions with BZD and Z-drug hypnotics were prescribed for patients aged 65 year 
or more. Of them, 44% of alprazolam, 51.1% of diazepam, 46% of estazolam, 41% of 
zolpidem, and 46% of zopiclone were prescribed for the elderly patients, respectively. 
In 2011, 40% of zolpidem users and 32% of zopiclone users were elderly. The top three 
prescribing specialists for Z-drugs were neurologist, cardiologist and psychiatrists 
in (accounted for 63.01% and 46.96% for zolpidem and zolpiclone, respectively). 
Of 12,982 patients being prescribed with 53,330 BZD and Z-drug prescriptions in 
2013, 76.9% were aged 65 year or more. The Z-drugs were still more common than 
BZD as a whole. ConClusions: While the elderly accounted for small proportion 
of medical care users, relatively larger proportions were prescribed with BZD and 
Z-drug hypnotics to manage their insomnia problems in CMUH across seven years. 
Further outcome assessments for such usage are necessary.
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Statin Medication uSe and tHe deVeloPMent of ProliferatiVe 
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The progression from Non-Proliferative Diabetic Retinopathy (NPDR) to Proliferative 
Diabetic Retinopathy (PDR) is associated with a decline in best-corrected visual 
acuity and related health care utilization. Few studies have systematically assessed 
the effect of pharmacological regimens in delaying the progression of PDR.  Many 
patients are also on chronic medication regimens which may also have tempo-
ral effects on the risk of disease progression.objeCtives: Examine how patients’ 
chronic medication utilization potentially influences their PDR progression among 
NPDR patients with type-2 diabetes, hypertension and hyperlipidemia in the 
United States. Methods: This retrospective cohort study was conducted using 
a claims database of all beneficiaries had any ophthalmic care and were enrolled 
in a large managed-care network from 2001 to 2012. Utilization of distinct oral 
hypoglycemic agents, blood pressure lowering agents and lipid lowering agents 
were measured by the total cumulative dosage of medication (g) within a three 
year moving window. A multivariate Cox regression analysis with medication use 
as a time-varying covariate assessed the association between medication use and 
progression to PDR. Results: A total of 10,845 NPDR patients with all of these 
three conditions were eligible for this study, and 837(7.72%) of them developed PDR 
during the follow up period. Increased use of Statins was associated with a signifi-
cant decreased hazard of developing PDR (Hazard Ratio: 0.995 95%CI [0.99–0.999], 
p< 0.05) after adjusting for demographic and clinical confounders. Patients with 
increased use of insulin had increased hazard of developing PDR (Hazard Ratio: 
1.002 95%CI [1.001-1.004], p< 0.01). Potential risk factors of PDR progression included 
HbA1c level and diabetes-related complications. ConClusions: By developing a 
time-dependent medication use model, our study provides important information 
on physicians’ prescribing strategies aimed at preventing PDR progression among 
patients with type-2 diabetes, hypertension and hyperlipidemia. Increasing adher-
ence to statins for patients diagnosed with all of these three components of meta-
bolic syndrome may be helpful for delaying their PDR progression.
HealtH SerViceS reSearcH StudieS
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objeCtives: To evaluate the impact of the use of guideline recommended care 
on the risk of subsequent moderate to severe COPD exacerbation requiring hospi-
talization or emergency department (ED) visit following discharge from COPD in a 
privately insured population in Texas. Methods: Retrospective population-based 
cohort study design using Blue Cross Blue Shield of Texas (BCBSTX) enrollment and 
claims data (years 2008 to 2011) was employed. All COPD-related hospitalizations 
and ED visits were extracted. Patients were identified as adherence to guideline 
recommended care if within 30 days of discharge, had at least one claim of pre-
scription fills for any maintenance medications and had at least one follow up visit 
with a primary care physician or pulmonologist. The presence of a subsequent 
COPD-related exacerbation requiring hospitalization or an ED visit was assessed for 
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dementia (weighted sample= 16,272) took any antipsychotic medications; 69.7% 
were female and 68.8% were white. The average age was 85 years.  Their physical 
functions were measured by the number activities of daily living (avg. 2.92) and 
number of instrumental activity of daily living (avg. 3.6).  The most frequent diag-
noses were Alzheimer’s disease (78.8%) and vascular dementia (23.2%).  I used the 
Neuropsychiatry Inventory (NPI) for behavior problems (delusions, hallucinations, 
agitation/aggression, depression, apathy, elation, anxiety, disinhibition, irritability/
lability, and aberrant motor behavior).  I evaluated severity of dementia using the 
Clinical Dementia Rating Scale (CDR). I found that older persons with dementia 
are significantly more likely to relocate to the nursing home in 2 years if they were 
severely demented (OR= 1.3, p< .05), or were on antipsychotic medications (OR = 1.0 
p< .05), or were getting older (OR= 0.01, p< .05).  But, those who were living with 
caregiver (OR= -1.8, p< .01), or were Hispanic (OR= -1.4 p< .01) were significantly 
less likely to move to nursing homes.  Alzheimer patients were significantly more 
likely to relocate to nursing home compared to vascular dementia patients (OR= 
-1.4, p< .05). ConClusions: Community-dwelling older persons with dementia are 
more likely to move to nursing home within 2 years if they had to be medicated for 
their behavior problems and were on antipsychotic medications and, the dementia 
is more advanced
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objeCtives: In China, memantine is only reimbursed for severe dementia, while 
approved for moderately severe to severe dementia. The present model assesses 
the clinical and economic outcomes of extending national recommendations for 
memantine to moderate dementia. Methods: A Markov model was developed to 
simulate transition between health states associated with dementia. Three alter-
native strategies - no treatment, memantine prescribed from moderate to severe, 
and memantine prescribed in severe only- were compared over a five-year time 
horizon for a cohort of 1,000 patients with moderate dementia. The proportions of 
severe, dependent or aggressive patients, and caregivers’time, were estimated as 
clinical outcomes. Total costs were estimated and compared as economic outcomes. 
Deterministic sensitivity analyses were conducted to test the robustness of model 
assumptions and parameters estimates. Data inputs were taken from multiple 
sources, including clinical trials and a Delphi panel. The model adopted societal 
perspective with only direct costs considered. Results: After five years, the cohort 
of patients administered memantine from the moderate stage had developed the 
lowest proportions of severe (45%), dependent (52%) and aggressive (7%) patients, 
and necessitated less caregiver’s time (6.7hours/day). In the cohort of patients 
administered memantine in the severe stage only, these estimates were higher 
(54%, 61%, 8% and 8.35 hours/day, respectively). There were higher in patients not 
treated (64%, 77%, 13% and 9.26hours/day). Starting from the third year, memantine 
started in moderate stage incurred the lowest costs. By year five, total costs were 
RMB 182.5, 197.0 and 200.0 million for memantine from moderate, memantine in 
severe only and no treatment respectively. The sensitivity analysis produced com-
parable results. ConClusions: Over five years, memantine consistently demon-
strated higher clinical benefit when administered in moderate to severe patients as 
compared to restricted to severe and showed increasing cost-savings after 2years 
mainly due to the avoided hospitalisations.
reSearcH PodiuM PreSentationS – SeSSion ii
cardioVaScular diSeaSe outcoMeS reSearcH StudieS
cV1
coMPariSon of oral VerSuS intraVenouS nSaidS for tHe treatMent 
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infantS: a SySteMatic reView and Meta-analySiS
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objeCtives: Intravenous Indomethacin and Ibuprofen are treatment of choice for 
pharmacologic closure of patent ductus arteriosus (PDA) in preterm infants accord-
ing to inhibitory effect on cyclooxygenase. However, unavailability of the intrave-
nous formulations in many countries leads to off-label use of oral NSAIDs for PDA 
closure. This study therefore aimed to determine the effectiveness and safety of oral 
NSAIDs compared to their intravenous formulations for PDA closure in preterm and/
or low birth weight infants. Methods: Randomized or quasi-randomized (RCTs) 
and observational studies comparing oral NSAIDs to intravenous Indomethacin or 
Ibuprofen with reported result of closure rate were identified. Fixed and random 
effect models were used for meta-analyses. Heterogeneity test including I2 were 
performed to assess the appropriateness of pooling the data. Results: Fourteen 
studies comparing the effectiveness and safety of oral NSAIDs (Indomethacin, 
Ibuprofen and Sulindac) with intravenous NSAIDs (Indomethacin and Ibuprofen) 
were recruited. For the primary outcome (closure rate), no statistically significant 
difference between oral Ibuprofen and intravenous NSAIDs group [five RCTs of oral 
Ibuprofen versus Intravenous Ibuprofen group; RR = 1.12 (95% CI 0.990, 1.240, I2 
23.1%)] and [four RCTs of oral Ibuprofen versus Intravenous Indomethacin group; 
RR = 1.035 (95% CI 0.755, 1.418, I2 12.7%)]. Results from the observational stud-
ies were also similar to those of RCTs. Two observational studies comparing oral 
Indomethacin and intravenous Indomethacin revealed no statistically significant 
difference (RR = 0.927 [95% CI 0.704, 1.22, I2 0.0%]). There was no significant dif-
ference in adverse outcome between oral and intravenous NSAIDs treatment 
saturation point was reached at 13 in Khyber Pakhtunkhwa province of Pakistan 
from December to February 2014. The interviews were conducted at the hospital 
pharmacy, arrangements for the time and place of interview were made during ini-
tial contacts. Written consent was obtained from the participants prior to the inter-
view. Results: Among the respondents interviewed, nine were male and four female 
hospital pharmacist aged between 25 and 50 years. Thematic content analysis yielded 5 
major themes: (a) Patients reporting (b) Lack of patient counseling (c) Lack of participa-
tion in health awareness programs, (d) Pharmacists reducing the prescribing errors, (e) 
Insufficient number of pharmacists. ConClusions: Findings revealed that hospital 
pharmacist in Pakistan are not actively participating in provision of pharmaceutical 
care services. They are facing significant hurdles for their actively participation in 
patient care, major obstacles is  the unavailability of sufficient number of pharmacist, 
lack of appropriate time for patient counseling and poor relationship between pharma-
cists and other health care providers. Moreover there is a need to explore the concept 
of pharmaceutical care among the other health care providers and general public.
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objeCtives: Paliperidone palmitate long-acting injectable (PP-LAI) is a new once-
monthly atypical antipsychotic for the treatment of schizophrenia. This article 
is to evaluate the efficacy and safety of PP-LAI in the treatment of schizophre-
nia. Methods: Published clinical studies concerning PP-LAI for schizophrenia 
were searched systemically and assessed by Jadad items. RevMan 5.2 software was 
used for data analysis and for calculating the combined outcomes of clinical tri-
als and their 95% Confidence Intervals (CI). Furthermore, sensitive analysis and 
publication bias test were conducted to assess the stability of results from Meta-
analysis. Results: 12 clinical randomized controlled trials including 39 analytic 
sets were selected for Meta-analysis. According to Jadad items, the qualities of 
including researches were high in which the rules of random grouping and balanc-
ing baseline characteristics between groups were conducted rigorously. The inci-
dence of effective cases in PP-LAI group was 1.7 (95%CI: 1.50-1.91) times higher than 
that in placebo group (Z= 8.55, P< 0.01) and equaled to the rate in risperidone group 
(RR= 1, 95%CI: 0.88-1.13). Compared with the control group of placebo (RR= 1.01, 
95%CI: 0.97-1.05) and risperidone (RR= 1.07, 95%CI: 0.98-1.16), PP-LAI seemed to 
be well tolerated, with the same incidence of adverse events. The stability of the 
present Meta-analysis was accepted without any statistical significance found by 
sensitive analysis and publication bias test. ConClusions: Paliperidone palmitate 
has certain efficacy and safety in the treatment of schizophrenia.
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objeCtives: Dementia is an irreversible brain disease that results in progressive 
cognitive impairment and, eventually, inability to carry out the simplest tasks of 
daily living. Currently there exists no cure for this disease. Patients suffering demen-
tia require plenty of care, mainly provided by the families. The objective of this 
study was to assess the time required from the patients’ caregivers according to the 
patient’s health state, and the consequences for the active population in current 
China. Methods: The current Chinese demographic structure was put in balance 
with the need of caregiving time needed by the dementia population. Demographic 
data, proportion of diagnosed and/or treated patients were provided the China 
Alzheimer’s project Memory360. A Markov model was developed to estimate the 
average caregiver’s time needed per patient per day over 5 years, separately for 
treated and not treated patients. Results: Current demographic situation in China 
is rather favourable with 70% of the population aged between 15 and 59 years (com-
pared to 60% in Europe or United States and 65% in Japan). There are approximately 
6 active persons for one elderly. It was demonstrated that over five years, untreated 
patient with dementia requires around 9.3 hours per day compared to 6.7 hours per 
day for a treated patient. It was estimated that there were 10 million patients with 
dementia in China, with only 21.3% among them receiving treatment. More than 
87 million hours per day are needed to take care of Chinese patients with dementia 
for around 910 million working people. ConClusions: In the current situation 
of China, it is estimated that in average one worker over ten will spend one hour 
per day providing care to a patient affected by dementia. Taking into account the 
rapidly aging population, this burden is likely to increase considerably in the future.
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objeCtives: This study examined factors of relocating to nursing homes among 
community-dwelling older persons with dementia. Methods: This retrospective 
study used data from The Aging, Demographics, and Memory Study (ADAMS) to 
assess dementia severity and service use from 2002 to 2004 in the United States. This 
study examined psychotropic medication use among 279 older people diagnosed 
with dementia and used logistic regressions to identify factors associated with 
nursing home relocation among older persons with dementia. Results: Among 
older persons with dementia (weighted sample = 177,843), 9.2 % of persons with 
